sales@angenesci.com
Login | Register
logo
Structures Search
Home Halogens 1-([1,1'-Biphenyl]-4-yl)-2-bromoethanone

1-([1,1'-Biphenyl]-4-yl)-2-bromoethanone

CAS No.:
135-73-9
Catalog Number:
AG003B6J
Molecular Formula:
C14H11BrO
Molecular Weight:
275.1405
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5g
98%(HPLC)
In Stock USA
United States
$78
- +
25g
98%(HPLC)
In Stock USA
United States
$190
- +
100g
98%(HPLC)
In Stock USA
United States
$540
- +
Product Description
Catalog Number:
AG003B6J
Chemical Name:
1-([1,1'-Biphenyl]-4-yl)-2-bromoethanone
CAS Number:
135-73-9
Molecular Formula:
C14H11BrO
Molecular Weight:
275.1405
MDL Number:
MFCD00000202
IUPAC Name:
2-bromo-1-(4-phenylphenyl)ethanone
InChI:
InChI=1S/C14H11BrO/c15-10-14(16)13-8-6-12(7-9-13)11-4-2-1-3-5-11/h1-9H,10H2
InChI Key:
KGHGZRVXCKCJGX-UHFFFAOYSA-N
SMILES:
BrCC(=O)c1ccc(cc1)c1ccccc1
EC Number:
205-217-6
NSC Number:
37117
Properties
Complexity:
225  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
273.999g/mol
Formal Charge:
0
Heavy Atom Count:
16  
Hydrogen Bond Acceptor Count:
1  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
275.145g/mol
Monoisotopic Mass:
273.999g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
17.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.6  
Literature
Title Journal
4,4'-Dibromo-2-nitro-biphen-yl. Acta crystallographica. Section E, Structure reports online 20120201
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. Journal of medicinal chemistry 20110623
2-Bromo-1-(3-nitro-phen-yl)ethanone. Acta crystallographica. Section E, Structure reports online 20110101
Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. Journal of medicinal chemistry 20031023
alpha-bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: structure-Activity relationship. Bioorganic & medicinal chemistry letters 20021104
Properties